Lenacapavir HIV prevention breakthrough raises access equity concerns

Lenacapavir, a twice-yearly injectable PrEP, is hailed as a major advance in HIV prevention, but its rollout will be uneven, raising questions about global access and pricing. The development is significant for public health but its market and geopolitical impact is limited.